Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371656 | 0.98 | ADH1C (0.38) | DPP4CYP1A2MAPK1ADH1BADH1C | |
| SCHEMBL25075552 | 0.91 | DPP4 (0.39) | DPP4CYP1A2MAPK1NOS3NOS1 | |
| SCHEMBL7447366 | 0.78 | ADH1C (0.38) | ADH1BADH1CADH1A | |
| SCHEMBL104547 | 0.73 | ADH1A (0.40) | ADH1BADH1CADH1A | |
| SCHEMBL13301673 | 0.73 | ADH1A (0.45) | ADH1BADH1CADH1A | |
| SCHEMBL6976549 | 0.71 | ADH1C (0.39) | ADH1BADH1CADH1A | |
| SCHEMBL13503176 | 0.71 | ADH1A (0.43) | ADH1BADH1CADH1A | |
| SCHEMBL17914493 | 0.71 | ADH1C (0.39) | ADH1BADH1CADH1A | |
| SCHEMBL23319699 | 0.71 | ADH1C (0.39) | ADH1BADH1CADH1A | |
| SCHEMBL736638 | 0.71 | ADH1C (0.39) | ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7094769-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2006-06-08 | — | — | US | disclosed |
| US-6921753-B2 | Purine derivatives | PFIZER INC (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040229838-A1 | Purine derivatives | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| US-6753322-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-06-22 | — | — | US | disclosed |
| US-6624158-B2 | Compound for use in the treatment of; sepsis, urogential, psychological, nervous system, respiratory, inflammatory, skin vascular and arthritic; wound healing agents | PFIZER INC | 2003-09-23 | — | — | US | disclosed |
| EP-1317465-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1296996-A1 | PURINE DERIVATIVES | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| EP-1292604-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | Pfizer Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-20020072597-A1 | Purine derivatives | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2002022630-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2002-03-21 | — | — | WO | disclosed |
| US-20020032168-A1 | Purine derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2002000676-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001094368-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229838-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | DPP4 1508/4885CYP1A2 208/4885MAPK1 1538/4885 |
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | DPP4 1345/4885CYP1A2 157/4885MAPK1 3672/4885 |
| US-20020032168-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | DPP4 1508/4885CYP1A2 208/4885MAPK1 1538/4885 |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A1 | DPP4 1576/4885CYP1A2 127/4885MAPK1 2185/4885 |
| US-20020072597-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | DPP4 1508/4885CYP1A2 208/4885MAPK1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.